Rare Daily Staff

Precision medicines biotech Maze Therapeutics said it completed a $190 million financing to support its Compass platform and advance the company’s nine precision medicines programs for both rare and common genetically defined diseases with high unmet need.

Matrix Capital Management led the financing with participation from General Catalyst, a16z Bio+Health, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and several others. In conjunction with the financing, Matrix Capital Management’s Andy Tran has joined the company’s board of directors.

Since its launch in 2019 with a financing led by Third Rock Ventures and ARCH Venture Partners, with participation from other investors, it has generated nine programs and two joint ventures.

Maze proprietary Compass purpose-built, end-to-end platform combines human genetic data, functional genomic tools, and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using Compass, Maze is building a broad portfolio, including wholly owned programs targeting Pompe disease, chronic kidney disease, and amyotrophic lateral sclerosis (ALS), as well as partnered programs in cardiovascular and ophthalmic diseases.

Proceeds from the financing will be used to support advancement of the company’s nine precision medicines programs for both rare and common genetically defined diseases with high unmet need, including its three most advanced programs, MZE001 for the treatment of Pompe disease, APOL1 program for the treatment of chronic kidney disease, and ATXN2 program for the treatment of ALS. Maze expects MZE001 to enter the clinic in the first half of 2022. Proceeds will also be used to further expand Maze Compass.

“Over the past year, Maze has generated data across multiple disease areas and modalities,” said Jason Coloma, president and CEO of Maze. “As we transition to a clinical-stage company, we believe this financing provides important resources to advance our pipeline and to uncover new genetic associations to develop precision medicines for patients with genetically defined diseases.”

Photo:

Maze Therapeutics Raises $190 Million to Advance Programs and Platform for Genetic Diseases

Rare Daily Staff

Precision medicines biotech Maze Therapeutics said it completed a $190 million financing to support its Compass platform and advance the company’s nine precision medicines programs for both rare and common genetically defined diseases with high unmet need.

Matrix Capital Management led the financing with participation from General Catalyst, a16z Bio+Health, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and several others. In conjunction with the financing, Matrix Capital Management’s Andy Tran has joined the company’s board of directors.

Since its launch in 2019 with a financing led by Third Rock Ventures and ARCH Venture Partners, with participation from other investors, it has generated nine programs and two joint ventures.

Maze proprietary Compass purpose-built, end-to-end platform combines human genetic data, functional genomic tools, and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using Compass, Maze is building a broad portfolio, including wholly owned programs targeting Pompe disease, chronic kidney disease, and amyotrophic lateral sclerosis (ALS), as well as partnered programs in cardiovascular and ophthalmic diseases.

Proceeds from the financing will be used to support advancement of the company’s nine precision medicines programs for both rare and common genetically defined diseases with high unmet need, including its three most advanced programs, MZE001 for the treatment of Pompe disease, APOL1 program for the treatment of chronic kidney disease, and ATXN2 program for the treatment of ALS. Maze expects MZE001 to enter the clinic in the first half of 2022. Proceeds will also be used to further expand Maze Compass.

“Over the past year, Maze has generated data across multiple disease areas and modalities,” said Jason Coloma, president and CEO of Maze. “As we transition to a clinical-stage company, we believe this financing provides important resources to advance our pipeline and to uncover new genetic associations to develop precision medicines for patients with genetically defined diseases.”

Photo: Jason Coloma, president and CEO of Maze

X